Alendronate conjugate for targeted delivery to bone-forming prostate cancer is a research paper published in Talanta (2023). On theSindex it has a DataRank of 0.360. It has been cited 10 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Heart, Lung, and Blood Institute
Grant: 5R01HL141831-03
National Heart, Lung, and Blood Institute
Grant: 1R01HL159960-01A1
National Cancer Institute
Grant: 5P50CA140388
National Cancer Institute
Grant: R01CA174798
National Cancer Institute
Grant: P30CA016672
Cancer Prevention and Research Institute of Texas
Grant: RP150179
Cancer Prevention and Research Institute of Texas
Grant: RP190252
NHLBI NIH HHS
Grant: R01 HL159960
NHLBI NIH HHS
Grant: R01 HL141831
NCI NIH HHS
Grant: P50 CA140388
National Institutes of Health
FWCI
1.14
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals